earnings
confidence high
sentiment positive
materiality 0.80
Hims & Hers FY2025 revenue up 59% to $2.35B, adj. EBITDA $318M; guides FY2026 rev $2.7-2.9B
Hims & Hers Health, Inc.
2025-FY EPS
reported $0.51
vs consensus $0.05
▲ beat
(+992.1%)
- Revenue $2.35B (+59% YoY); net income $128M; adj. EBITDA $318M vs $177M prior year.
- Q4 revenue $618M (+28% YoY); net income $20.6M; adj. EBITDA $66.3M.
- Subscribers at 2.5M (+13% YoY); monthly revenue per avg subscriber $83 (+28% YoY).
- FY2026 guidance: revenue $2.7-2.9B, adj. EBITDA $300-375M; excludes potential Eucalyptus acquisition.
- Non-GLP-1 revenue majority; compounded semaglutide access assumed in guidance.